전문정보검색
| No | 제목 / 내용 |
|---|---|
| 1 |
Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by ma Surgery, Pemetrexed, Paclitaxel, Oncology, Medicine, Lung cancer, Internal medicine, Hazard ratio, Clinical trial, Carboplatin, Beva |
| 2 |
Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary He Low-frequency coding DNA sequence variants in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) lower plasma low-density |
| 3 |
Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in ex Oligonucleotide therapies offer precision treatments for a variety of neurological diseases, including epilepsy, but their deployment |
| 4 |
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic derma |
| 5 |
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic derma |
| 6 |
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic derma atopic dermatitis, atopic eczema, ciclosporin, daily practice, dupilumab, effectiveness, ethnicity, methotrexate, morphology, race, |
| 7 |
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic derma Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types.To investiga |
| 8 |
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic derma Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types.To investiga |
| 9 |
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic derma 6 < = > P n (P 68 NL No an by in of on vs 156 235 DST Few LST and any for had may the use 1-3, 25%, 29.0 4-6, 9.7; Area DST. EASI Skin |
| 10 |
Acute Kidney Injury in Patients Receiving Pembrolizumab Combination Therapy versus Pembrolizumab The addition of the immune checkpoint inhibitor (ICPi), pembrolizumab, to standard pemetrexed- and platinum-based chemotherapy has imp |